Skip to main content
Register
Medicine Matters Diabetes
TOOLBAR 1 2 3 4
SEARCH
MENU 1 2 3 4
Close search form
main-content

Medication

Alpha-glucosidase inhibitors

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

06-27-2018 | Hyperglycemia | Article

Contribution of BHG and PPHG to overall hyperglycemia in T2DM patients treated with LM25 and LM50: Post hoc analysis of a randomized crossover trial

Li W et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0462-9

06-01-2018 | Diet | Article

Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA1c in individuals with and without diabetes

 Færch K et al. Nutr Diabetes 2018; 8: 38. doi: 10.1038/s41387-018-0047-8

05-08-2018 | Pregnancy | Review | Article

Pharmacotherapy for hyperglycemia in pregnancy: Do oral agents have a place?

Corcoy R et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.04.015

01-04-2018 | Medication adherence | Article

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study

McGovern A et al. Diabetes Ther 2018; 9: 229–242. doi: 10.1007/s13300-017-0361-5

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

07-31-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Xu J, Rajaratnam R. Cardiovasc Diabetol 2017; 16: 18. doi: 10.1186/s12933-017-0499-5


More on diabetes medications


« Back to main page | Adherence | Adverse effects | Alpha-glucosidase inhibitors | Amylin analogs | Anti-hypertensive medications | Anti-obesity medications | Cardiovascular disease | Clinical trials | Diabetic complications | DPP-4 inhibitors | Gestational diabetes and pregnancy | Glinides | GLP-1 receptor agonists | Glycemic control | Guidelines | Healthcare costs | Insulins | Lipid-lowering medications | Metformin | Oral combination medications | Other medication classes | Pediatrics | SGLT2 inhibitors | Specific populations | Sulfonylureas | Thiazolidinediones | Type 1 diabetes | Type 2 diabetes


image credits

Version: 201802052232-1107